{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-189569","form_type":"8-K","ticker":"VCNX","cik":"0001205922","company_name":"VACCINEX, INC.","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.362399+00:00","generated_at":"2026-05-31T14:16:49.003189+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vaccinex reports positive SIGNAL-AD Phase 1b/2 data for pepinemab in Alzheimer's","bullets":["Primary safety endpoint met: pepinemab well-tolerated; no serious treatment-related adverse events.","Secondary endpoint: statistically significant increase in FDG-PET signal in medial temporal cortex (p=0.0297) in MCI patients over 12 months.","Results echo prior Phase 2 Huntington's data, suggesting similar mechanism targeting astrocyte activation.","Company actively pursuing a pharmaceutical partner for late-stage development in Alzheimer's disease.","Pepinemab has been well-tolerated in over 600 patients across AD, HD, and MS trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-189569","json":"https://secwatch.observer/filing/0001193125-24-189569.json","markdown":"https://secwatch.observer/filing/0001193125-24-189569.md","text":"https://secwatch.observer/filing/0001193125-24-189569.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1205922/000119312524189569/0001193125-24-189569-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1205922/000119312524189569/d858316d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:16:49.003189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}